What is the risk of clinically significant bleeding associated with low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of ACS patients?
Low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of ACS patients had similar risks of clinically significant bleeding (5%) as aspirin and a P2Y12 inhibitor (HR, 1.09; 95% CI, 0.80-1.50; P .5840).